Virág László
Department of Medical Chemistry, Research Center for Molecular Medicine, Medical and Health Science Center, University of Debrecen, Bem tér 18/B, Hungary.
Curr Vasc Pharmacol. 2005 Jul;3(3):209-14. doi: 10.2174/1570161054368625.
Poly(ADP-ribosyl) ation is a reversible post-translational protein modification implicated in the regulation of a number of biological functions. Whereas an 18 member superfamily of poly(ADP-ribose) polymerase (PARP) enzymes synthesize poly(ADP-ribose) (PAR), a single protein, PAR glycohydrolase (PARG) is responsible for the catabolism of the polymer. PARP-1 accounts for more than 90% of the poly(ADP-ribosyl)ating capacity of the cells. PARP-1 activated by DNA breaks cleaves NAD(+) into nicotinamide and ADP-ribose and uses the latter to synthesize long branching PAR polymers covalently attached to acceptor proteins including histones, DNA repair enzymes, transcription factors and PARP-1. Whereas activation of PARP-1 by mild genotoxic stimuli may facilitate DNA repair and cell survival, irreparable DNA damage triggers apoptotic or necrotic cell death. In apoptosis, early PARP activation may assist the apoptotic cascade [e.g. by stabilizing p53, by mediating the translocation of apoptosis inducing factor (AIF) from the mitochondria to the nucleus or by inhibiting early activation of DNases]. In most severe oxidative stress situations, excessive DNA damage causes over activation of PARP-1, which incapacitates the apoptotic machinery and switches the mode of cell death from apoptosis to necrosis. Besides serving as a cytotoxic mediator, PARP-1 is also involved in transcriptional regulation, most notably in the NF kappaB and AP-1 driven expression of inflammatory mediators. Pharmacological inhibition or genetic ablation of PARP-1 provided remarkable protection from tissue injury in various oxidative stress-related disease models ranging from stroke, diabetes, diabetic endothelial dysfunction, myocardial ischemia-reperfusion, shock, Parkinson's disease, arthritis, colitis to dermatitis and uveitis. These beneficial effects are attributed to inhibition of the PARP-1 mediated suicidal pathway and to reduced expression of inflammatory cytokines and other mediators (e.g. inducible nitric oxide synthase).
聚(ADP-核糖)化是一种可逆的翻译后蛋白质修饰,与多种生物学功能的调节有关。虽然有一个由18个成员组成的聚(ADP-核糖)聚合酶(PARP)酶超家族可合成聚(ADP-核糖)(PAR),但单一蛋白质聚(ADP-核糖)糖苷水解酶(PARG)负责该聚合物的分解代谢。PARP-1占细胞聚(ADP-核糖)化能力的90%以上。DNA断裂激活的PARP-1将NAD(+)切割成烟酰胺和ADP-核糖,并利用后者合成与包括组蛋白、DNA修复酶、转录因子和PARP-1在内的受体蛋白共价连接的长分支PAR聚合物。虽然轻度基因毒性刺激激活PARP-1可能促进DNA修复和细胞存活,但无法修复的DNA损伤会引发凋亡或坏死性细胞死亡。在凋亡过程中,早期PARP激活可能有助于凋亡级联反应[例如通过稳定p53、介导凋亡诱导因子(AIF)从线粒体转运至细胞核或抑制DNase的早期激活]。在最严重的氧化应激情况下,过量的DNA损伤会导致PARP-1过度激活,从而使凋亡机制失效,并将细胞死亡模式从凋亡转变为坏死。除了作为细胞毒性介质外,PARP-1还参与转录调控,最显著的是参与NF-κB和AP-1驱动的炎症介质表达。在从中风、糖尿病、糖尿病性内皮功能障碍、心肌缺血再灌注、休克、帕金森病、关节炎、结肠炎到皮炎和葡萄膜炎等各种氧化应激相关疾病模型中,PARP-1的药理学抑制或基因敲除为组织损伤提供了显著的保护。这些有益作用归因于对PARP-1介导的自杀途径的抑制以及炎症细胞因子和其他介质(如诱导型一氧化氮合酶)表达的降低。